JP2017523784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523784A5 JP2017523784A5 JP2017505792A JP2017505792A JP2017523784A5 JP 2017523784 A5 JP2017523784 A5 JP 2017523784A5 JP 2017505792 A JP2017505792 A JP 2017505792A JP 2017505792 A JP2017505792 A JP 2017505792A JP 2017523784 A5 JP2017523784 A5 JP 2017523784A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- amino acid
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033045P | 2014-08-04 | 2014-08-04 | |
| US62/033,045 | 2014-08-04 | ||
| US201562164783P | 2015-05-21 | 2015-05-21 | |
| US62/164,783 | 2015-05-21 | ||
| PCT/US2015/042986 WO2016022400A1 (en) | 2014-08-04 | 2015-07-30 | T cell immunotherapy specific for wt-1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018142600A Division JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523784A JP2017523784A (ja) | 2017-08-24 |
| JP2017523784A5 true JP2017523784A5 (enExample) | 2018-09-06 |
| JP6712261B2 JP6712261B2 (ja) | 2020-06-24 |
Family
ID=53901124
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505792A Expired - Fee Related JP6712261B2 (ja) | 2014-08-04 | 2015-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
| JP2018142600A Pending JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018142600A Pending JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10538572B2 (enExample) |
| EP (1) | EP3177314B1 (enExample) |
| JP (2) | JP6712261B2 (enExample) |
| CN (1) | CN107074970B (enExample) |
| CA (1) | CA2956545A1 (enExample) |
| ES (1) | ES2841274T3 (enExample) |
| WO (1) | WO2016022400A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102415259B1 (ko) * | 2013-11-22 | 2022-06-30 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 조작된 고-친화도의 인간 t 세포 수용체 |
| EP4406604A3 (en) * | 2015-03-05 | 2024-10-23 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| US10975436B2 (en) | 2016-01-05 | 2021-04-13 | Diamir, Llc | Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders |
| SMT202200306T1 (it) | 2016-04-08 | 2022-09-14 | Immunocore Ltd | Recettori di cellule t |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| EP3548055A4 (en) | 2016-12-02 | 2020-08-19 | University of Southern California | SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE |
| CN110121336A (zh) | 2017-01-05 | 2019-08-13 | 弗莱德哈钦森癌症研究中心 | 改善疫苗功效的系统和方法 |
| TW201835100A (zh) * | 2017-02-06 | 2018-10-01 | 國立研究開發法人國立癌症研究中心 | 新穎ｔ細胞受體 |
| JP7037577B2 (ja) * | 2017-03-15 | 2022-03-16 | フレッド ハッチンソン キャンサー リサーチ センター | 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 |
| CN119409836A (zh) | 2017-03-17 | 2025-02-11 | 弗雷德哈钦森癌症中心 | 免疫调节融合蛋白及其用途 |
| JP7328211B2 (ja) | 2017-04-24 | 2023-08-16 | オスペダーレ サン ラファエレ エス．アール．エル | Ｔｃｒ及びペプチド |
| WO2019004831A1 (en) * | 2017-06-30 | 2019-01-03 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
| NL2019156B1 (en) * | 2017-06-30 | 2019-01-10 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Treatment of haematological malignancies |
| CN107267463A (zh) * | 2017-08-23 | 2017-10-20 | 安徽惠恩生物科技股份有限公司 | 一种针对乳腺癌的Car‑NK细胞制备方法 |
| SG11202002481RA (en) | 2017-09-19 | 2020-04-29 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing gene expression in eukaryotic cells |
| JP2020537515A (ja) | 2017-10-03 | 2020-12-24 | ジュノー セラピューティクス インコーポレイテッド | Ｈｐｖ特異的結合分子 |
| CN109777778B (zh) * | 2017-11-14 | 2023-07-18 | 中国科学院广州生物医药与健康研究院 | 一种基因改造的γδT细胞 |
| MX2020006119A (es) | 2017-12-21 | 2020-08-24 | Hoffmann La Roche | Anticuerpos de union a hla-a2/wt1. |
| DE112019000348B4 (de) | 2018-01-05 | 2021-10-28 | Nantbio, Inc. | Umprogrammierte t-zellen ähnliche nk-zellen |
| KR20250099256A (ko) | 2018-01-18 | 2025-07-01 | 프레드 허친슨 캔서 센터 | 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경 |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| CN112040986A (zh) | 2018-03-15 | 2020-12-04 | Ksq治疗公司 | 用于改进的免疫疗法的基因调控组合物和方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| EP3773908A1 (en) * | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
| MA52207A (fr) * | 2018-04-05 | 2021-02-17 | Editas Medicine Inc | Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| EP3833681A1 (en) * | 2018-08-06 | 2021-06-16 | Medigene Immunotherapies GmbH | Ha-1 specific t cell receptors and their use |
| WO2020049496A1 (en) * | 2018-09-05 | 2020-03-12 | Glaxosmithkline Intellectual Property Development Limited | T cell modification |
| CA3115240A1 (en) | 2018-10-05 | 2020-04-09 | International Institute Of Cancer Immunology, Inc. | Composition for preventing or treating benign tumor |
| CN113227374A (zh) | 2018-10-16 | 2021-08-06 | 因特利亚治疗公司 | 用于免疫疗法的组合物和方法 |
| GB201817821D0 (en) * | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| GB201819540D0 (en) | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| WO2020185796A1 (en) | 2019-03-11 | 2020-09-17 | Fred Hutchinson Cancer Research Center | High avidity wt1 t cell receptors and uses thereof |
| CN111714618B (zh) * | 2019-03-22 | 2024-07-12 | 香雪生命科学技术（广东）有限公司 | T细胞和高亲和力pd-1融合蛋白的组合 |
| EP3750547A1 (en) * | 2019-06-13 | 2020-12-16 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Modified nk-92 cells, and therapeutic and diagnostic uses thereof |
| JP7737978B2 (ja) * | 2019-08-20 | 2025-09-11 | フレッド ハッチンソン キャンサー センター | Ｗｔ－１に特異的なｔ細胞免疫療法 |
| KR102842684B1 (ko) * | 2019-12-30 | 2025-08-05 | 브리스타 이뮤노테크 리미티드 | 향상된 t-세포 수용체 star 및 이의 적용 |
| CN114106144B (zh) * | 2020-08-27 | 2024-01-26 | 溧阳瑅赛生物医药有限公司 | 识别hla-a*02/wt1靶点的tcr及其应用 |
| WO2022132836A2 (en) | 2020-12-14 | 2022-06-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| AU2022260698A1 (en) * | 2021-04-21 | 2023-11-09 | Oxford University Innovation Limited | Method and composition |
| WO2022246250A1 (en) * | 2021-05-20 | 2022-11-24 | Washington University | Neuroprotective compositions and methods |
| JP2024525727A (ja) | 2021-07-14 | 2024-07-12 | ２セブンティ バイオ インコーポレイテッド | 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体 |
| CN113773378B (zh) * | 2021-10-14 | 2023-11-03 | 深圳大学总医院 | T细胞受体及其应用 |
| US20240390423A1 (en) * | 2021-10-29 | 2024-11-28 | Yafei Hou | T cell receptor recognizing s37f mutation in ctnnb1 and its application |
| CA3255500A1 (en) | 2022-04-08 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | MULTI-PART RECEIVERS AND SIGNALING COMPLEXES |
| KR20250070621A (ko) | 2022-08-18 | 2025-05-20 | 이뮤노코어 리미티드 | Mage-a4에 특이적인 t 세포 수용체 융합 단백질 |
| EP4609202A2 (en) * | 2022-10-28 | 2025-09-03 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ewsr1-wt1 fusion protein and uses thereof |
| WO2024178397A2 (en) | 2023-02-24 | 2024-08-29 | Elevatebio Technologies, Inc. | Modified immune effector cells and methods of use |
| KR20260033032A (ko) | 2023-06-29 | 2026-03-10 | 디스패치 바이오테라퓨틱스, 인크. | 합성 시토카인 수용체 |
| WO2025240518A1 (en) | 2024-05-14 | 2025-11-20 | Dispatch Biotherapeutics, Inc. | Modified lentiviral transfer plasmids |
| GB202406990D0 (en) * | 2024-05-16 | 2024-07-03 | Univ Oxford Innovation Ltd | T cell receptors and uses thereof |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
| WO2026006767A1 (en) | 2024-06-28 | 2026-01-02 | Dispatch Biotherapeutics, Inc. | Tethered il-9/il-9r and related engineered cells and methods |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| AU4932199A (en) | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
| GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| WO2004024175A1 (ja) | 2002-09-12 | 2004-03-25 | Haruo Sugiyama | 癌抗原ペプチド製剤 |
| US7575925B2 (en) | 2002-12-10 | 2009-08-18 | Sunnybrook Health Sciences Centre | Cell preparations comprising cells of the T cell lineage and methods of making and using them |
| PT1731605E (pt) | 2004-03-31 | 2010-04-14 | Int Inst Cancer Immunology Inc | Péptidos antigénicos de cancro derivados de wt1 |
| JP2008527001A (ja) | 2005-01-13 | 2008-07-24 | ザ ジョンズ ホプキンス ユニバーシティー | 前立腺幹細胞抗原ワクチンおよびその使用 |
| DK2352756T3 (da) | 2008-11-24 | 2012-12-03 | Helmholtz Zentrum Muenchen | Højaffin T-cellereceptor og anvendelse af denne |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| HRP20171164T1 (hr) * | 2010-09-20 | 2017-10-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t stanični receptori i t stanični epitopi |
| EP2844743B1 (en) * | 2012-05-03 | 2021-01-13 | Fred Hutchinson Cancer Research Center | Enhanced affinity t cell receptors and methods for making the same |
| KR102499753B1 (ko) | 2012-07-27 | 2023-02-16 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | Ｔ 세포 수용체 조작 |
| CA2899679C (en) * | 2013-01-29 | 2023-03-21 | Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch | High avidity antigen recognizing constructs |
-
2015
- 2015-07-30 ES ES15753531T patent/ES2841274T3/es active Active
- 2015-07-30 EP EP15753531.1A patent/EP3177314B1/en active Active
- 2015-07-30 US US14/813,782 patent/US10538572B2/en active Active
- 2015-07-30 CA CA2956545A patent/CA2956545A1/en active Pending
- 2015-07-30 JP JP2017505792A patent/JP6712261B2/ja not_active Expired - Fee Related
- 2015-07-30 CN CN201580049647.6A patent/CN107074970B/zh active Active
- 2015-07-30 WO PCT/US2015/042986 patent/WO2016022400A1/en not_active Ceased
-
2018
- 2018-07-30 JP JP2018142600A patent/JP2018183175A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523784A5 (enExample) | ||
| JP7157839B2 (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
| Johdi et al. | Colorectal cancer immunotherapy: options and strategies | |
| JP7223055B2 (ja) | 癌治療のための併用免疫療法及びサイトカイン制御療法 | |
| Baxevanis et al. | Cancer immunotherapy | |
| Dotti et al. | Design and development of therapies using chimeric antigen receptor‐expressing T cells | |
| Di et al. | Combined adjuvant of poly I: C improves antitumor effects of CAR-T cells | |
| Zeltsman et al. | CAR T-cell therapy for lung cancer and malignant pleural mesothelioma | |
| Redeker et al. | Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination | |
| JP2020509767A5 (enExample) | ||
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| CN111989118B (zh) | 包含耗竭性抗cd4单克隆抗体的抗癌t细胞治疗剂辅助用组合物及其用途 | |
| Bernatchez et al. | Advances in the treatment of metastatic melanoma: adoptive T-cell therapy | |
| JP2016520074A5 (enExample) | ||
| JP2017531687A5 (enExample) | ||
| WO2018193119A1 (en) | Gene therapy | |
| WO2017159736A1 (ja) | 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター | |
| JP2021512637A5 (enExample) | ||
| JP2020533962A5 (enExample) | ||
| Zhang et al. | Genetic engineering with T cell receptors | |
| JP2023524853A5 (enExample) | ||
| Danhof et al. | CARs and other T cell therapies for MM: the clinical experience | |
| JP2022525099A5 (enExample) | ||
| Dhodapkar et al. | Hematologic malignancies: plasma cell disorders | |
| Brayer et al. | Developing strategies in the immunotherapy of leukemias |